Targeted therapy of respiratory syncytial virus by 2-5A antisense (Q45423099)

14 December 2017

Targeted therapy of respiratory syncytial virus by 2-5A antisense (English)

1 reference

14 December 2017

Hagen Cramer

1

1 reference

14 December 2017

James R Okicki

series ordinal

2

1 reference

14 December 2017

Mei Kuang

series ordinal

3

1 reference

14 December 2017

Zan Xu

series ordinal

4

1 reference

14 December 2017

1 January 2005

1 reference

Nucleosides, Nucleotides & Nucleic Acids

14 December 2017

1 reference

14 December 2017

24

1 reference

14 December 2017

5-7

1 reference

14 December 2017

497-501

1 reference

Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order

14 December 2017

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200061780

Respiratory syncytial virus (RSV) disease and prospects for its control

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200061780

Respiratory syncytial virus infection in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200061780

Treatment of RSV pneumonia in adults--evidence of ribavirin effectiveness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200061780

2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200061780

Targeting RNA decay with 2',5' oligoadenylate-antisense in respiratory syncytial virus-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200061780

Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200061780

Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200061780

Targeting RNA for degradation with a (2'-5')oligoadenylate-antisense chimera

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200061780

Recruiting the 2-5A system for antisense therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200061780

Potent inhibition of respiratory syncytial virus by combination treatment with 2-5A antisense and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200061780

Evaluation of the toxicity and antiviral activity of carbocyclic 3-deazaadenosine against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200061780

Further studies with short duration ribavirin aerosol for the treatment of influenza virus infection in mice and respiratory syncytial virus infection in cotton rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200061780

Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200061780

Blockage of NF-kappa B signaling by selective ablation of an mRNA target by 2-5A antisense chimeras

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200061780

21 January 2018

Identifiers

DOI

10.1081/NCN-200061780

1 reference

14 December 2017

1 reference